Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan and Thalidomide in Recurrent Malignant Gliomas
NCT00014443Phase 2Terminated
- Sponsor
- Rush University Medical Center
- Start
- Aug 2000
- Primary completion
- Aug 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide and topotecan in malignant glioma, sponsored by Rush University Medical Center. Primary endpoints: Tumor Response Rate and Safety and Tolerance. Started Aug 2000; status: terminated.
02
Drugs
thalidomidetopotecan
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00014443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00014443.